Skip to main content
Top
Published in: Advances in Therapy 12/2023

Open Access 04-10-2023 | Paroxysmal Nocturnal Hemoglobinuria | Correction

Correction to: Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison

Authors: Raymond Wong, Jesse Fishman, Koo Wilson, Michael Yeh, Mohammed Al-Adhami, Abigail Zion, Christopher W. Yee, Lynn Huynh, Mei Sheng Duh

Published in: Advances in Therapy | Issue 12/2023

Login to get access

Excerpt

Correction to: Adv Ther (2023) 40:1571–1589 https://doi.org/10.1007/s12325-023-02438-9
Metadata
Title
Correction to: Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison
Authors
Raymond Wong
Jesse Fishman
Koo Wilson
Michael Yeh
Mohammed Al-Adhami
Abigail Zion
Christopher W. Yee
Lynn Huynh
Mei Sheng Duh
Publication date
04-10-2023
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 12/2023
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-023-02640-9

Other articles of this Issue 12/2023

Advances in Therapy 12/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine